Global Non-Hodgkin Lymphoma Diagnostics Market - Industry Trends and Forecast to 2030
The global Non-Hodgkin lymphoma diagnostics market is projected to register a substantial CAGR of 8.5% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market SegmentationGlobal Non-Hodgkin Lymphoma Diagnostics Market, By Test Type (Imaging, Biopsy, Immunohistochemistry, Biomarker Test, Genetic Test, Cytogenetics, Lumbar Puncture (Spinal Tap), Blood Test and Cytochemistry), Cancer Stage (Stage IV, Stage III, Stage II, Stage I, and Stage 0), Tumor Type (Aggressive Lymphomas and Indolent Lymphomas), Product (Instrument Based Products, Platform Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa)Industry Trends and Forecast to 2030
Some of the major factors contributing to the growth of the global non-Hodgkin lymphoma diagnostics market are:• Increased growth in the prevalence of Non-Hodgkin Lymphoma
• Advancement in artificial intelligence in the diagnosis of non-Hodgkin lymphoma
Market PlayersSome of the major players operating in the global non-Hodgkin lymphoma diagnostics market are: • CANON MEDICAL SYSTEMS CORPORATION
• Koninklijke Philips N.V.
• Siemens Healthcare GmbH
• Danaher.
• Bio-Rad Laboratories, Inc.
• General Electric Company
• Sysmex Corporation
• Grail
• F. Hoffmann-La Roche
• Neusoft Corporation
• Agilent Technologies, Inc.
• NeoGenomics Laboratories
• Hologic, Inc
• Integrated DNA Technologies, Inc.
• CENTOGENE N.V.
• Merit Medical Systems
• Invitae Corporation
• PerkinElmer Inc.
• QIAGEN
• GeneDx, LLC
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Please note: This publisher does offer titles that are created upon receipt of order. The report will take approximately 15-20 business days to prepare and deliver.